Close Menu

This article has corrected to include recent data presented by Freenome on the sensitivity and specificity of its test across earlier and later stage colorectal cancer cases.


NEW YORK – Researchers shared new data this week from a study of the colorectal cancer screening test being developed by CellMax life, providing the first prospective sensitivity and specificity evidence for the assay in an intended use population in the US.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.